Scarica l'app Stockscreener
3.03
0.00%
0.00
Dopo l'orario di chiusura:
3.02
-0.010
-0.33%
Precedente Chiudi:
$3.03
Aprire:
$3.1
Volume 24 ore:
356.19K
Relative Volume:
0.44
Capitalizzazione di mercato:
$216.78M
Reddito:
-
Utile/perdita netta:
$-104.08M
Rapporto P/E:
-2.1537
EPS:
-1.4069
Flusso di cassa netto:
$-89.91M
1 W Prestazione:
+14.77%
1M Prestazione:
-1.94%
6M Prestazione:
+68.33%
1 anno Prestazione:
+71.67%
Intervallo 1D:
$3.005
$3.22
Intervallo di 1 settimana:
$2.60
$3.22
Portata 52W:
$1.63
$3.65
Nkarta Inc Stock (NKTX) Company Profile
Nome
Nkarta Inc
Settore
Industria
Telefono
(925) 407-1049
Indirizzo
1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO
Compare NKTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NKTX
Nkarta Inc
|
3.03 | 216.78M | 0 | -104.08M | -89.91M | -1.4069 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nkarta Inc Stock (NKTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-15 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-10-09 | Iniziato | Rodman & Renshaw | Buy |
| 2024-08-14 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-03-22 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2022-12-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-10-10 | Iniziato | Canaccord Genuity | Buy |
| 2022-07-28 | Iniziato | Needham | Buy |
| 2022-07-18 | Iniziato | SVB Leerink | Outperform |
| 2022-03-11 | Iniziato | Raymond James | Outperform |
| 2022-03-08 | Iniziato | H.C. Wainwright | Buy |
| 2022-01-06 | Iniziato | William Blair | Outperform |
| 2021-11-18 | Iniziato | SMBC Nikko | Outperform |
| 2021-07-16 | Iniziato | Oppenheimer | Outperform |
| 2020-08-04 | Iniziato | Cowen | Outperform |
| 2020-08-04 | Iniziato | Evercore ISI | Outperform |
| 2020-08-04 | Iniziato | Mizuho | Buy |
| 2020-08-04 | Iniziato | Stifel | Buy |
Mostra tutto
Nkarta Inc Borsa (NKTX) Ultime notizie
Nkarta Inc. (NKTX) Holds Steady at $3.03 as Market Awaits CatalystATR Stop - Newser
Nkarta (NKTX) Posts Record Q1 2026 — EPS $-0.37 Blows Past EstimatesRising Community Picks - newser.com
NEA (NKTX) drops below 5% ownership in latest Schedule 13D/A filing - Stock Titan
Nkarta Insider Stock Sellers Must Be Relieved As Market Cap Falls To US$201m - simplywall.st
Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation - Yahoo Finance
Nkarta Price Target Maintained With a $11.00/Share by Needham - Moomoo
Nkarta, Inc. Stock 12‑Month Price Target Raised to $11.8, Implies 260% Upside - TradingView
Nkarta (NASDAQ:NKTX) Q1 2026 Narrower Loss Beats Estimates as Autoimmune Trial Advances - ChartMill
Nkarta (NASDAQ: NKTX) Q1 2026 loss narrows as cash reaches $266.7M - Stock Titan
Nkarta Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Nkarta, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results - Weekly Voice
Nkarta (NKTX) Q1 2026 results: NKX019 trial progress and cash runway into 2029 - Stock Titan
Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights - The Manila Times
FDA deal lets Nkarta test autoimmune cell therapy in community clinics - Stock Titan
TradingKey - TradingKey
How Nkarta (NKTX) performance compares to expectations (Momentum Fading) 2026-05-08Social Buzz - newser.com
NKTX stock up on upbeat regulatory update on lead autoimmune program - MSN
Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of "Hold" by Analysts - MarketBeat
NKTX Q1'26 Earnings: revenue estimate is 0 USD - TradingView
NKTX Nkarta reports wider than expected Q4 2025 loss, shares fall nearly 3% on weak investor sentiment.AI Stock Signals - Newser
Nkarta (NASDAQ:NKTX) Stock Price Down 3.1%Here's Why - MarketBeat
[ARS] Nkarta, Inc. SEC Filing - Stock Titan
Executive pay, auditor and board elections on ballot at Nkarta (NKTX) 2026 virtual meeting - Stock Titan
NKTX (Nkarta Inc.) reports wider than expected Q4 2025 loss, shares jump nearly 16 percent on upbeat investor sentiment.Retail Trader Ideas - Cổng thông tin điện tử Tỉnh Sơn La
Nkarta cell therapy trial may soon offer outpatient treatment option in AAV - ANCA Vasculitis News
Nkarta (NKTX) Stock Dividend Safety (Underperforming) 2026-04-20Crowd Trend Signals - Xã Thanh Hà
Nkarta (NKTX) Stock: Why It Could Change (In Focus) 2026-04-18Professional Trade Ideas - Cổng thông tin điện tử tỉnh Lào Cai
Nkarta (NKTX) Stock: Is It Stabilizing (In Focus) 2026-04-18Trend Following Picks - Newser
NKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune Program - The Globe and Mail
Nkarta receives FDA agreement for outpatient NKX019 dosing By Investing.com - Investing.com India
Should I buy Nkarta (NKTX) - Zacks Investment Research
Stifel Maintains Nkarta(NKTX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Nkarta wins FDA nod for new trial protocol (NKTX:NASDAQ) - Seeking Alpha
symbol__ Stock Quote Price and Forecast - CNN
Needham Maintains Nkarta(NKTX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers - Sahm
NKTX: Pivot to off-the-shelf CAR-NK therapy in autoimmune diseases, with broad trials and strong cash runway - TradingView
Nkarta announces FDA agreement on outpatient dosing of NKX019 in autoimmune disease, expanding access to community rheumatology centers - marketscreener.com
Nkarta receives FDA agreement for outpatient NKX019 dosing - Investing.com
Nkarta Reports FDA Agreement on Outpatient Dosing of NKX019 - marketscreener.com
Nkarta targets 2-hour monitoring, not overnight stays, in cell therapy trials - Stock Titan
CEO Moves: Will Nkarta Inc stock benefit from M A2026 Investor Takeaways & Technical Pattern Alert System - baoquankhu1.vn
If You Invested $1,000 in Nkarta, Inc. (NKTX) - Stock Titan
Aug PostEarnings: Is Nkarta Inc stock suitable for long term investing2026 Big Picture & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Nkarta to Participate in Needham Virtual Healthcare Conference - Bitget
Nkarta leaders to discuss autoimmune cell therapy at Needham event - Stock Titan
Ideas Watch: Does Nkarta Inc have declining or rising EPSGap Down & High Win Rate Trade Tips - baoquankhu1.vn
Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight - GlobeNewswire Inc.
Nkarta Inc Azioni (NKTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.98%
1.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):